scholarly journals Phase 2 trial (BRF113928) of dabrafenib (D) plus trametinib (T) in patients (pts) with previously untreated BRAF V600E–mutant metastatic non-small cell lung cancer (NSCLC)

2017 ◽  
Vol 28 ◽  
pp. v637 ◽  
Author(s):  
D. Planchard ◽  
E.F. Smit ◽  
H.J.M. Groen ◽  
J. Mazieres ◽  
B. Besse ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Braf V600e ◽  
Phase 2 ◽  
Small Cell Lung ◽  
Phase 2 Trial

Neoadjuvant atezolizumab and chemotherapy in patients with resectable non-small-cell lung cancer: an open-label, multicentre, single-arm, phase 2 trial

2020 ◽  
Vol 21 (6) ◽  
pp. 786-795 ◽  
Author(s):  
Catherine A Shu ◽  
Justin F Gainor ◽  
Mark M Awad ◽  
Codruta Chiuzan ◽  
Claud M Grigg ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Phase 2 ◽  
Small Cell Lung ◽  
Open Label ◽  
Phase 2 Trial

scholarly journals Randomized phase 2 trial of erlotinib in combination with high-dose celecoxib or placebo in patients with advanced non-small cell lung cancer

Cancer ◽  
2015 ◽  
Vol 121 (18) ◽  
pp. 3298-3306 ◽  
Author(s):  
Karen L. Reckamp ◽  
Marianna Koczywas ◽  
Mihaela C. Cristea ◽  
Jonathan E. Dowell ◽  
He-Jing Wang ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
High Dose ◽  
Phase 2 ◽  
Small Cell Lung ◽  
Phase 2 Trial ◽  
Randomized Phase 2

DISRUPT: A randomised phase 2 trial of ombrabulin (AVE8062) plus a taxane–platinum regimen as first-line therapy for metastatic non-small cell lung cancer

Lung Cancer ◽  
2014 ◽  
Vol 85 (2) ◽  
pp. 224-229 ◽  
Author(s):  
Joachim von Pawel ◽  
Vera Gorbounova ◽  
Martin Reck ◽  
Dariusz M. Kowalski ◽  
Aurore Allard ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Phase 2 ◽  
Small Cell Lung ◽  
First Line ◽  
First Line Therapy ◽  
Phase 2 Trial ◽  
Line Therapy
Sign in / Sign up

Export Citation Format

Share Document